ReviewTrends in cardiovascular medicine2017
Leveraging human genetics to guide drug target discovery.
Review in Trends in cardiovascular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Connecting to improve drug discovery.Nature cardiovascular research · 2026Article
- Rare coding variants in CHRNB2 reduce the likelihood of smoking.Nature genetics · 2023Article
- Multi-level advances in databases related to systems pharmacology in traditional Chinese medicine: a 60-year review.Frontiers in pharmacology · 2023Review
- Emerging Targets for Cardiovascular Disease Prevention in Diabetes.Trends in molecular medicine · 2020Review
- Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist.Internal and emergency medicine · 2018Article
- Loss-of-function of neuroplasticity-related genes confers risk for human neurodevelopmental disorders.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2018Article
- The genetics of obstructive sleep apnoea.Respirology (Carlton, Vic.) · 2018Review
- Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities.International journal of epidemiology · 2017Article
- Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges.PLoS genetics · 2017Review
- ANGPTL3 Deficiency and Protection Against Coronary Artery Disease.Journal of the American College of Cardiology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
Identifying appropriate molecular targets is a critical step in drug development. Despite many advantages, the traditional tools of observational epidemiology and cellular or animal models of disease can be misleading in identifying causal pathways likely to lead to successful therapeutics. Here, we review some favorable aspects of human genetics studies that have the potential to accelerate drug target discovery. These include using genetic studies to identify pathways relevant to human disease, leveraging human genetics to discern causal relationships between biomarkers and disease, and studying genetic variation in humans to predict the potential efficacy and safety of inhibitory compounds aimed at molecular targets. We present some examples taken from studies of plasma lipids and coronary artery disease to highlight how human genetics can accelerate therapeutics development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.